Proud to Provide Chronic Pain Management for Our Military Personnel

If you are a military patient or medical professional, please look below at Brian Yanik’s experience while a patient at the Center for the Intrepid – Brooke Army Hospital in San Antonio. When finished, look at the Clinical Studies tab.

Brian Yanik

Brian Yanik’s 7 years with InterX

Watch Video
Brian Yanik Case Study

Case Study

Brian’s medical team published a case study about his treatment in The Pain Practitioner magazine

View Case Study
Brian Yanik Medical Report

Medical Report

Brian was given this medical report and has allowed us to show it

View Case Study

In the Clinical Studies section of this website five studies are listed.  All five, in addition to reporting pain reduction, reported reductions in anti-inflammatory medications required. One summary is shown below.

Study Medication
low grade ankle sprain etoricoxib 60 mg
Bimalleolar ankle fracture ketorolac
Plantar Fasciitis etoricoxib 60 mg
TKR ketorolac
Trochanteric fracture ketorolac

TABLE II. The mean (range) post-operative intake of Ketorolac in both groups

Day NIN* group Sham group
1 3.47 (3to4) 4.47 (4to5)
2 3.07 (2to4) 4.07 (3to5)
3 2.63 (2to3) 3.77 (3to4)
4 2.03 (1to3) 3.27 (2to4)
5 1.53 (1to2) 2.87 (2to4)
6 1.07 (0to2) 2.57 (2to3)
7 0.73 (0to1) 2.17 (1to3)
8 0.47 (0to1) 1.77 (1to2)
9 0.13 (0to1) 1.33 (1to2)
10 0.00 (0to0) 0.87 (0to1)

*NIN, non-invasive interactive neurostimulation

feet

“About 30sec into it he told me to look at my foot and it was a normal skin tone color. First time it had been in awhile…”

When pain is reduced, need for pain medications follows.

In a 50-patient study of total knee arthroplasty medication was measured on a morphine equivalence scale, male patients in the active group reduced their pain medication intake by 55% and female patients by 13%.

The Brian Yanik video and Pain Practitioner article, and medical case report all report elimination of opioid medication.  Brian’s medical case history states:

 (7 months after patient started InterX)…”the pain was well controlled and he was subsequently discharged from the pain clinic. His medication regimen now eliminated opioids and included pregabalin 50mg twice daily and 100mg at night. The SM reported continued self-treatment daily with the devices….”

A study of 22 severe chronic orthopedic patients (no controls) was conducted over a 3-day period with InterX.  15 of the 22 patients experienced a large reduction in pain.

The patients in this study achieved a sustained response that lasted at least 24 hours in between treatments. This was demonstrated by the numeric pain score reductions of AV, PAS and Illicit pre-treatment on Day 2 as compared to pre-treatment Day 1 of 28%, 19% and 18% respective. On Day 3 as compared to Day 2 the pre-treatment scores of AV, PAS, and Illicit improved by an additional 27%, 27% and 23% respectively. These results indicate that, for most patients, the effects of a 30-minute treatment are sustained for at least 24 hours between treatments. The long-term effects and longevity of response need to be further evaluated”. 

Although opioids were not the subject of the study, it was noted that ten patients began the study on significant pain medication (opiates or derivatives and duragesic patches). 

“Of the group, four patients required duragesic patches. Forty percent (40%) of the patients voluntarily reduced their pain medication requirements (Table 6). Interestingly all of the patients on the duragesic patches voluntarily discontinued the use within the first 24 hours of the study. An additional patient who underwent a shoulder disarticulation, who was semi-lethargic on numerous pain medications, was lucid and had dramatically decreased his pain medication requirement throughout the treatment period.”

This pilot study is not included in the Clinical Studies section of this website, but can be seen here.

InterX has not had a full clinical study of its effectiveness on CRPS/RSD, but there is a lot of informal support.  Brian Yanik’s video and Pain Practitioner article, plus his medical case history, are strong.  Here is the conclusion of the Pain Practitioner article:

“Our hope is that this case provides preliminary support for the use of Alpha-Stim and InterX for rapid reduction in CRPS severity.”

Informal support is also given by two video case histories:

Linsey Heidelberg video features before, during, and after footage of the InterX treatment, and includes statements by her physician.

Linsey case history

A recent case involves a teenager who developed CRPS.  The Mayo Clinic diagnosed the CRPS, but did not treat it.

There are a half dozen other videos of InterX treatment of CRPS at this link: RSD CRPS Recovery Stories – YouTube

alert

Inflammation, opioids, and CRPS

InterX has not applied for FDA approval on these conditions; as a smaller medical device manufacturer, a large study is out of our budget range. Currently we are seeking funding for clinical studies on these medical problems. Below is some evidence that studies are worthwhile.